Iteos Home

Pipeline

Home / Pipeline

Cancer immunotherapies by design, and in development.

Our two clinical-stage product candidates, EOS-448 and Inupadenant, each target a key mechanism that inhibits an effective antitumor immune response: a novel checkpoint TIGIT and the ATP adenosine pathway, respectively. We believe that both product candidates have the potential to further increase patient responses to standard cancer therapies, including immunotherapy. We are evaluating numerous biomarkers in our clinical programs to maximize this potential through choosing synergistic combination agents and identifying patients most likely to benefit from our product candidates.

We are also using our deep understanding of the critical immune resistance pathways to identify new targets and generate additional differentiated programs for underexploited pathways validated by a strong scientific rationale.

More about our pipeline

Our pipeline

Our efforts are targeting various cancer indications using our drug candidates either in monotherapy or in combination with additional drugs, as well as in intraportfolio combinations.

The following information provides an overview of our dynamic pipeline of cancer therapy development. Studies underway are grouped by our primary drug therapies, and listed out by combination with other treatments. Indications for each combination under study, along with the current and planned phases of each study, are included.

iTeos drug trials move through five phases:

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

iTeos drug trials move through five phases:

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

Following is a list of drug combinations currently under study with:

EOS-448

as well as the indication for each.

drug combo and indication:

+ dostarlimab | 1L NSCLC PDL1high

status of study phases:

Phase 3, planned

drug combo and indication:

+ dostarlimab | 1L NSCLC PDL1high | NCT05565378

status of study phases:

Phase 2, active trial ID NCT05565378

drug combo and indication:

+ dostarlimab | 1L HNSCC PDL1high / low | TIG-006

status of study phases:

Phase 2, active, trial ID TIG-006

drug combo and indication:

+ dostarlimab + chemotherapy | 1L mNSCLC | TIG-006

status of study phases:

Phase 1, active, trial ID TIG-006

drug combo and indication:

+ dostarlimab + CD96 | Advanced Malignancies | NCT03739710

status of study phases:

Phase 1, active, trial ID NCT03739710

drug combo and indication:

+ dostarlimab + PVRIG | Advanced Malignancies | NCT05277051

status of study phases:

Phase 1, active, trial ID NCT05277051

drug combo and indication:

Monotherapy/+ iberdomide | Relapsed Refractory Multiple Myeloma | TIG-007

status of study phases:

Phase 2, active, trial ID TIG-007

Following is a list of drug combinations currently under study with:

Inupadenant

as well as the indication for each.

drug combo and indication:

Monotherapy | High Biomarker | IO-001

status of study phases:

Phase 2, active, trial ID IO-001

drug combo and indication:

+ chemotherapy | Post-IO Chemo-naive NSCLC | A2A-005

status of study phases:

Phase 2, active, trial ID A2A-005

Following is a list of drug combinations currently under study with:

EOS-984

as well as the indication for each.

drug combo and indication:

Monotherapy | Advanced Malignancies

status of study phases:

Phase 1, planned

Studies with dark backgrounds are active. Studies with light backgrounds are planned.

Child kissing older woman on cheek.

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

At iTeos, we believe that collaboration is critical to achieve our mission of developing breakthrough therapies. By building upon our talents and expertise, bringing out the best in each other, and working synergistically with the best scientists and technologies.

We bring our deep understanding of the tumor microenvironment and immunosuppressive pathways to design new products and improve the clinical benefit of oncology therapies.